Home > Boards > Stock Clubs > Technical Analysis > QualityStocks

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
QualityStocks Member Profile
 
Followed By 423
Posts 43,302
Boards Moderated 2
Alias Born 05/08/06
160x600 placeholder
Correction to Indianapolis Shooting Article
Rupal Thanawala is a 25-year Indianapolis resident originally from Mumbai. "After FedEx Shooting, Indianapolis Grieves" at 1:07 p.m. and 5:30 p.m. ET incorrectly said she is 25 years old. The Indy 1500 Gun & Knife Show was held Saturday. "After FedEx Shooting, Indianapolis Grieves" at 1:07 p.m. and 5:30 p.m. ET incorrectly referred to the event as the Indy 500 Gun and Knife Show.
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 11th Update
Correction to Indianapolis Mass Shooting Article
Correction to Indianapolis Shooting Article at 1:07 p.m. ET
After FedEx Shooting, Indianapolis Grieves
Travel Boom Coming, Expedia CEO Says: 'Hotels Will Come Screaming Back'
Expat Americans Fly Home for Covid-19 Vaccination Shots
In Punishing Russia for SolarWinds, Biden Upends U.S. Convention on Cyber Espionage
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 10th Update
Roger Stone Is Sued as U.S. Government Alleges Unpaid Taxes -- Update
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 9th Update
Roger Stone Is Sued as U.S. Government Alleges Unpaid Taxes
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 8th Update
Top Company News of the Day
J&J, Morgan Stanley, Coinbase: Stocks That Defined the Week
NASA Picks SpaceX to Build New Lunar Lander -- 2nd Update
Lilly Ends U.S. Use of Single Covid-19 Antibody Drug Alone -- Update
Indianapolis Mass Shooting: At Least Eight Dead at FedEx Facility -- 7th Update
Stocks End Week With Fresh Records--Update
Top Stories of the Day
NASA Picks SpaceX to Build New Lunar Lander -- Update
FedEx's Limits on Phones in Spotlight After Indianapolis Shooting
QualityStocks   Tuesday, 07/07/20 06:01:23 PM
Re: None
Post # of 26891 
Compensated Awareness Post - View Disclaimer
QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, QM developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs. “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” Dr. Carl Schwartz, Predictive Oncology’s CEO, stated in the news release. “Integrating QM’s proven machine learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers. We will be able to more quickly understand how specific types of tumors react to cancer drug therapies. This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”

To view the full press release, visit http://ibn.fm/TUszu

About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences